Development of Patient-Derived Colorectal Cancer Xenograft and Organoid Models with Acquired Resistance to KRAS G12C Inhibitors

被引：0
|
作者：
Hua, L. [1 ]
Zheng, J. [2 ]
Wang, J. [1 ]
Shang, L. [3 ]
Qian, W. [4 ]
Sun, Y. [3 ]
Bourre, L. [5 ]
Wang, J. [1 ]
机构：
[1] Crown Biosci Inc, Canc Pharmacol, San Diego, CA USA
[2] Crown Biosci Inc, Oncol In Vivo, San Diego, CA USA
[3] Crown Biosci Inc, In Vivo, San Diego, CA USA
[4] Crown Biosci Inc, Data Sci & Bioinformat, San Diego, CA USA
[5] Crown Biosci Inc, Res & Innovat, San Diego, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114789
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB262
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [21] G12C KRAS mutant colorectal cancer, optimising the target
    Price, T. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1300 - S1300
  • [22] KRAS G12C inhibition with sotorasib in metastatic colorectal cancer
    Severi, Christophe
    Van Cutsem, Eric
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (08) : 2792 - 2795
  • [23] Concurrent inhibition of KRAS G12C and ERK1/2 overcomes acquired resistance to KRAS G12C inhibitors (G12Cis) conferred by various genetic alterations
    Wang, W.
    Lim, S. M.
    Yu, M. R.
    Cho, B. C.
    Chen, C.
    Wu, W.
    Zhang, J.
    Chen, Z. J.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S118 - S118
  • [24] Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
    Mohanty, Atish
    Nam, Arin
    Srivastava, Saumya
    Jones, Jeff
    Lomenick, Brett
    Singhal, Sharad S.
    Guo, Linlin
    Cho, Hyejin
    Li, Aimin
    Behal, Amita
    Mirzapoiazova, Tamara
    Massarelli, Erminia
    Koczywas, Marianna
    Arvanitis, Leonidas D.
    Walser, Tonya
    Villaflor, Victoria
    Hamilton, Stanley
    Mambetsariev, Isa
    Sattler, Martin
    Nasser, Mohd W.
    Jain, Maneesh
    Batra, Surinder K.
    Soldi, Raffaella
    Sharma, Sunil
    Fakih, Marwan
    Mohanty, Saswat Kumar
    Mainan, Avijit
    Wu, Xiwei
    Chen, Yihong
    He, Yanan
    Chou, Tsui-Fen
    Roy, Susmita
    Orban, John
    Kulkarni, Prakash
    Salgia, Ravi
    SCIENCE ADVANCES, 2023, 9 (41)
  • [25] Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
    Lee, Catherine
    Jiang, Ziyue Karen
    Planken, Simon
    Manzuk, Lisa K.
    Ortiz, Roberto
    Hall, Michael
    Noorbehesht, Kavon
    Ram, Sripad
    Affolter, Timothy
    Troche, Gabriel E.
    Ihle, Nathan T.
    Johnson, Theodore
    Ahn, Youngwook
    Kraus, Manfred
    Giddabasappa, Anand
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (07) : 891 - 900
  • [26] ONCOGENIC KRAS G12C MUTATION DERIVED INHIBITOR DEVELOPMENT
    Leveles, Ibolya
    Koppany, Gergely
    Nyiri, Kinga
    Vertessy, G. Beata
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2019, 75 : E117 - E117
  • [27] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
    Marinelli, D.
    Pisegna, S.
    Giammaruco, M.
    Chesi, P.
    Mammone, G.
    Ceddia, S.
    Gazzaniga, P.
    Cortesi, E.
    Gelibter, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
  • [28] Targeting KRAS G12C with Covalent Inhibitors
    Ostrem, Jonathan M. L.
    Shokat, Kevan M.
    ANNUAL REVIEW OF CANCER BIOLOGY, 2022, 6 : 49 - 64
  • [29] The Emerging Role of KRAS G12C Inhibitors in the Treatment of Locally Advanced or Metastatic Colorectal Cancer
    Ciombor, Kristen
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (08) : 503 - 505
  • [30] Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance
    Patel, Hetika Vora
    Smith, Alison
    Chan, Stacia
    Kessler, Linda
    Burrows, Francis
    Malik, Shivani
    CANCER RESEARCH, 2023, 83 (07)
12345